all‐trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial Academic Article Article uri icon

Overview

MeSH Major

  • CA-125 Antigen
  • Fallopian Tube Neoplasms
  • Ovarian Neoplasms
  • Peritoneal Neoplasms
  • Preoperative Care
  • Tomography, X-Ray Computed

abstract

  • A Phase II clinical trial of RA failed to show significant clinical antitumor activity in patients with chemotherapy-refractory GCTs. However in vitro data suggest that the control of growth and maturation in some GCT cell lines involve the RA signaling pathway. Further studies are warranted to define the role that other retinoids with receptor selectivity or more favorable pharmacologic properties may play in the maturation or antitumor responses of GCTs.

publication date

  • January 1995

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19950815)76:4<680::AID-CNCR2820760423>3.0.CO;2-9

PubMed ID

  • 8625166

Additional Document Info

start page

  • 680

end page

  • 6

volume

  • 76

number

  • 4